Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

NPIL Mulls Drug Discovery Spin-Off

September 3, 2007 | A version of this story appeared in Volume 85, Issue 36

Mumbai-based Nicholas Piramal India Ltd. is considering whether to turn its drug discovery research unit into a separate entity. Employing many Indian researchers recruited from the U.S., NPIL is one of India's most research-focused pharmaceutical companies. In July, the firm announced that it had an investigational new drug undergoing clinical trials at Harvard University's Dana-Farber Cancer Institute for treatment of multiple myeloma. One of the deadliest forms of cancers, myeloma is so far untreatable for most patients.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.